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Introduction: Etravirine is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) 
specifically designed to suppress the replication of viruses resistant to the three currently 
approved NNRTIs efavirenz, nevirapine, and delavirdine.
Aims: To assess the evidence for the place of etravirine in the treatment of HIV-1 infection.
Evidence review: In combination with a ritonavir-boosted protease inhibitor etravirine has 
demonstrated high antiviral activity against strains exhibiting up to three NNRTI resistance 
mutations. The drug appears to be well tolerated, with only nausea and rash occuring significantly 
more frequently with etravirine compared with placebo. Of note, neuropsychologic side effects 
that frequently limit the use of efavirenz were not reported more frequently with etravirine.
Place in therapy: Given its high activity against most NNRTI-resistant strains and its very 
good tolerability, etravirine is of high value for pretreated patients with NNRTI resistance and 
protease inhibitor exposure. Efforts should be made to demonstrate activity in switching strate-
gies (due to toxicity) and earlier lines of failure or in the setting of primary NNRTI resistance 
in order to explore the potential of the drug beyond salvage therapy.
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Core evidence place in therapy summary for etravirine treatment in HIV-1 
infection
Outcome measure Evidence Implications
Patient-oriented evidence
improvement of survival Some Superior viral load reduction and CD4+ 
T-cell increase most likely results in 
survival benefit (generally accepted 
surrogate markers)
Absence of cutaneous allergic 
reactions
Limited rash also observed with etravirine, no 
direct comparison with other NNrTi
Absence of neuropsychiatric 
side effects
Clear Frequency of neuropsychiatric side 
effects with etravirine same as with 
placebo
Few treatment 
discontinuations
Clear Side effects infrequent and virologic 
failure less likely with etravirine
Disease-oriented evidence
Superior viral load suppression Clear Etravirine use associated with improved 
virus suppression
Superior CD4+ T-cell 
reconstitution
Clear Etravirine use associated with superior 
increase in CD4+ T-cell counts
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Scope, aims, and objectives
Etravirine was licensed by the FDA in January 2008 
under the trade name IntelenceTM.1 It is currently licensed 
in the US, Canada, and Switzerland, and in the European 
Union. It belongs to the chemical class of diarylpyrimidine 
compounds and acts as a nonnucleoside reverse transcrip-
tase inhibitor (NNRTI), which inhibits the enzyme in a 
noncompetitive way. The aim of this article is to summarize 
current knowledge about the development of etravirine and 
to discuss its role in the treatment of HIV-1 infection.
Methods
The medical literature and the meeting abstracts of major 
scientific conferences on infectious diseases since Janu-
ary 1, 2003 were reviewed with regard to contributions on 
etravirine (formerly TMC125 or R165335, manufactured by 
Tibotec, a division of Janssen Cilag). In view of the rapid 
advances in the field of HIV treatment, meeting abstracts 
and internet communications were also included. PubMed 
(http://www.ncbi.nlm.nih.gov/sites/entrez) was searched 
using the search term “etravirine or TMC125 or TMC-
125.” In addition, homepages of major conferences on HIV 
infection and infectious diseases (www. retroconference.
org; www.iasociety.org/AbstractSearch.aspx; HIV Drug 
Resistance Workshop 2008: http://www.hivpresentation.
com/index.cfm; European AIDS Clinical Society: http://
www.eacs.eu/index_ns.htm; Interscience Conference on 
Antimicrobial Agents and Chemotherapy: http://www.icaac.
org/) were searched for abstracts including the search term. 
If primary scientific sources were unavailable, information 
compiled in company documents was added. Table 1 shows 
the results of the literature search and the records considered 
for this review.
Disease overview
HIV-1 infection is still spreading on a worldwide level. 
The Joint United Nations Programme on HIV/AIDS 
(UNAIDS) estimates 33.2 million people are living with 
HIV infection worldwide,2 the majority of whom are 
infected with HIV-1 and reside in subSaharan Africa and 
South-East Asia. Several countries of the former Soviet Union 
show rapidly increasing numbers of infected people, mainly 
in intravenous drug users. In those countries affected, HIV 
infection has serious consequences for both the individuals 
and the societies. Individually, it results in social marginaliza-
tion, poverty, and inability to work and sustain the economic 
basis of living for those infected and their families. For societ-
ies, the loss of young adults in the midst of their productive 
years and the secondary costs due to healthcare and child-
hood poverty markedly reduce the economic development 
perspectives.
Despite long-standing prevention campaigns, HIV infec-
tion continues to spread in the US and Western Europe as 
well. Highly active antiretroviral therapy (HAART), which 
is widely available in developed countries, has massively 
improved morbidity and mortality in those infected.3,4 It can 
control virus replication for many years in the individual. 
The associated burden of healthcare costs, especially for 
antiretroviral drugs, is increasingly being viewed as a chal-
lenge to healthcare systems.
(Continued)
Outcome measure Evidence Implications
Economic evidence
Cost-effectiveness in salvage 
therapy
Limited Benefit probable, but not enough 
evidence
Cost-effectiveness in early 
therapy
No evidence More costly than efavirenz and 
nevirapine, more evidence required
Abbreviation: NNrTi, nonnucleoside reverse transcriptase inhibitor.
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 114 57
  records excluded 93 46
  records included 21 11
Additional studies identified 3
Level 1 clinical evidence
Level 2 clinical evidence 6 1
Level  3 clinical evidence 11 10
trials other than rCT
Case studies 1
Notes:  For  definition  of  levels  of  evidence,  see  Core  Evidence  website 
(http://www.dovepress.com/core-evidence-journal). 
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 151
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Fortunately, the overall rate of resistance against 
antiretroviral drugs in treated patients appears not to 
increase,4–8 probably due to more rational use and a wider 
spectrum of agents available to achieve optimal virus 
inhibition. However, transmission of resistant virus strains 
remains a problem in newly infected individuals,6 ,9 resulting 
in suboptimal response.10,11
Current therapy options
The choice of the antiretroviral regimen is highly individualized 
and based on considerations such as primary resistance, the 
probability of treatment interruptions or nonadherence, drug 
interactions with HIV and concomitant medication, as well 
as on patient desires. There is broad consensus on the aim of 
achieving and maintaining a viral load that is undetectable 
with the most sensitive standard assays once antiretroviral 
therapy has been initiated. Initial treatment should comprise 
two nucleoside/nucleotide reverse transcriptase inhibitors. The 
third drug should either be an NNRTI or a protease inhibitor. 
There is some indication of a better virologic response with 
the NNRTI efavirenz, but more resistance in case of failure, 
often associated with cross resistance within the drug class.12 
In later lines of therapy, individual tolerance and the resistance 
profile of the virus determine the choice of drugs. Therefore, 
beyond initial therapy, most drugs that retain antiviral activity, 
are tolerated sufficiently well, and have no unfavorable 
pharmacokinetic interactions are used as combination partners. 
In this setting, drugs are added rather than exchanged. Due to 
their low genetic hurdle to resistance, NNRTIs are not used 
frequently beyond first-or second-line therapy.
Most protease inhibitors, NNRTIs, and nucleoside/
nucleotide reverse transcriptase inhibitors are licensed for 
all lines of therapy. The novel, less cross-resistant protease 
inhibitors tipranavir and darunavir, the fusion inhibitor 
enfuvirtide, the R5 coreceptor blocker maraviroc, and the 
integrase inhibitor raltegravir, however, are currently licensed 
for later lines only. Accordingly, clinical trial results mainly 
reflect their use in salvage therapy, with an ∼50%–100% 
increase of virologic response rates over placebo when the 
respective compound is added to a background combination 
selected according to the patient’s virus resistance genotype 
(“optimized background”). All NNRTIs except etravirine 
(ie, efavirenz, nevirapine, and delavirdine) are highly cross 
resistant and require only 1–2 mutations in viral reverse 
transcriptase in order to lose their activity almost completely 
(ie, they have a low “genetic hurdle”).13,14 The key NNRTI 
mutation K103N is rapidly selected for during failure of the 
most widely used NNRTI efavirenz, facilitated by reduced 
adherence,15 and confers cross resistance to nevirapine and 
delavirdine. It has little impact on viral replication capacity,16 
whereas protease inhibitor and nucleoside reverse transcriptor 
inhibitor mutations reduce it.17–21 In the absence of therapy, 
this loss of viral “fitness” leads to counter-selection in favor of 
wild-type virus and to the virtual disappearance of resistance 
mutations in genotypic resistance analyses.22 However, they 
remain present as minor variants probably indefinitely.23–25
The R5 coreceptor blocker, maraviroc, is only active 
in patients with no evidence of virus strains using the X4 
coreceptor. It has demonstrated high activity in two parallel 
trials, in which it was added to an optimized background 
regimen (MOTIVATE-1 and -2).26 In later lines of therapy, 
however, half of the patients carry viruses using either both the 
R5 and the X4 coreceptor or only X4,27 rendering maraviroc 
inactive. Even in antiretroviral naïve patients, 18% exhibited 
X4 use.28 Moreover, the drug failed to demonstrate equivalence 
to efavirenz (both in combination with zidovudine and lamivu-
dine) in antiretroviral naïve patients (MERIT study),29 probably 
due to emergence of X4-using variants undetected at baseline.30 
Maraviroc is also a substrate of CYP3A4. Therefore, dose 
adjustment is necessary when combined with inducers (eg, 
most NNRTIs) or inhibitors of CYP3A4 (eg, ritonavir).31
Raltegravir, the first licensed HIV integrase inhibitor, has 
demonstrated high antiviral activity when added to an opti-
mized background regimen in patients with virologic failure 
and resistant virus.32–34 In contrast to maraviroc, raltegravir 
showed equivalent virologic suppression when compared 
with efavirenz in previously untreated patients. It is mainly 
metabolized by UGT1A1;35 despite minor interactions, dose 
adjustment is not considered necessary in combination with 
other antiretroviral drugs.36
Unmet needs
Patients who develop extended antiretroviral drug resistance 
need as many virologically active agents as possible in order 
to compose a regimen with two or more active drugs. As 
outlined above for maraviroc, R5 inhibitors only represent 
an option in some patients. Moreover, in clinical routine, 
toxicity issues often prevent the use of some active drugs, so 
that the number of viable options for the individual may be 
substantially smaller than predicted by the resistance geno-
type. Therefore, there is a general need for many potentially 
active compounds to be available.
Development of novel compounds from within an exist-
ing class has the advantage of exploiting a well established 
treatment principle with less risk of unexpected toxicities than 
for compounds with novel modes of action. Accordingly, the Core Evidence 2009:4 152
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protease inhibitors tipranavir and darunavir were developed 
to target viruses resistant against earlier generations of 
protease inhibitors.
Due to broad cross resistance within the group of 
NNRTIs, a promising second-line NNRTI treatment option 
was lacking. Such an option is attractive because it should 
help to overcome the limitations of the low genetic hurdle 
and cross resistance of efavirenz, nevirapine, and delavirdine. 
Furthermore, should transmitted NNRTI resistance increase, 
novel, less cross-resistant compounds would be needed even 
in early lines of therapy.
Clinical evidence with etravirine
Etravirine is a diarylpyrimidine compound that was 
specifically designed to bind to HIV-1 reverse trancriptase 
in a more flexible manner than efavirenz and nevirapine and 
to require more than one key NNRTI resistance mutation for 
resistance development37–39(ie, to possess a higher genetic 
hurdle to resistance).
A phase I/II 7-day monotherapy trial in 19 HIV-infected, 
antiretroviral-naïve subjects showed a -1.99 log10 decline 
in HIV plasma viremia with etravirine as opposed to -0.06 
log10 in controls.40 A similar open-label phase IIa trial in 16 
individuals on a failing regimen containing efavirenz or nevi-
rapine and with documented phenotypic NNRTI resistance 
yielded a median plasma HIV RNA reduction of -0.89 log10.41 
Study TMC125-C203 was a randomized, phase IIb, placebo-
controlled, two-stage trial evaluating safety, tolerability, and 
preliminary efficacy of three twice-daily doses of etravirine42 
(400, 800, and 1200 mg twice daily of the phase II TF035 
formulation). No evidence of relevant neuropsychiatric side 
effects was found, and virus load suppression was superior at 
week 24 in the etravirine arm in stage II of the trial.43
The TMC125-C223 trial investigated two doses of etra-
virine (400 and 800 mg twice daily) versus placebo, com-
bined with an optimized background regimen in 199 patients 
with genotypic NNRTI resistance and at least three primary 
protease inhibitor resistance-associated mutations. Viral load 
reductions were -1.04 and -0.18 log10 in the etravirine arms 
compared with -0.19 log10 in the comparator arm.44
The phase IIb study, TMC125-C227, investigated the 
antiviral activity of etravirine in 116 treatment-experienced, 
protease inhibitor-naïve HIV-1 infected patients with 
genotypic evidence of NNRTI resistance at screening or 
in prior resistance analyses. The study was a randomized, 
exploratory, active-controlled, open-label comparison of 
etravirine (n = 59) and a protease inhibitor chosen by the 
investigator (n = 57). It was conducted in South Africa, South 
America, Asia, and Europe and used a different formulation 
of etravirine for which, however, exposure was comparable 
to the phase III formulation that is currently approved.45 The 
suppression rate of HIV plasma viremia to 50 copies/mL 
at week 12 was superior in the control arm (52%) compared 
with the etravirine arm (22%). This is explained by a higher 
number of mutations conferring resistance to NNRTI and 
to the nucleoside analogue backbone of the regimen.46 
Pretreatment definitely reduced the overall genetic hurdle 
to resistance against an NNRTI-based regimen in the study 
participants, so that fewer mutational steps had to be taken 
for the virus with etravirine. The hypothesis may be raised, 
however, that the evolutionary cost for the virus in terms of 
replicative fitness when acquiring new NNRTI mutations 
could be less than for protease inhibitor resistance mutations. 
This could contribute to a more rapid development of resis-
tance on etravirine than expected. Etravirine, therefore, is 
unlikely to be sufficiently active in patients who have been 
left on a failing NNRTI-based regimen for longer and should 
be combined with other active compounds.
Etravirine was licensed based on the analyses of 24-week 
data from two randomized, double-blind, placebo-controlled, 
phase III trials (TMC125-C206 and TMC125-C216), generally 
referred to as DUET-1 and DUET-2.47,48 Both trials were 
designed identically and results are presented here as a pooled 
analysis. A total of 1203 treatment-experienced patients 
were randomly assigned to receive etravirine (n = 599) or 
placebo (n = 604) in combination with a background regimen 
(BR) comprising the novel protease inhibitor darunavir, 
pharmacologically boosted with ritonavir 100 mg twice daily. 
Two additional investigator-selected agents had to be given, 
with or without enfuvirtide. Patients were eligible if their HIV 
plasma viral load was greater than 5000 copies/mL while on a 
stable antiretroviral regimen for at least 8 weeks. In addition, 
patients had 1 NNRTI resistance-associated mutations at 
screening or documented in a prior genotypic analysis, and  3 
of the primary protease inhibitor resistance-associated mutations 
D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/
F/L/S/T, I84V, N88S, or L90M. Randomization was stratified 
according to the intended use of enfuvirtide in the BR, previous 
use of darunavir/ritonavir, and screening viral load. Virologic 
response was defined as an undetectable viral load (50 HIV-1 
RNA copies/mL) at week 24.
In the pooled analysis, demographics and baseline 
characteristics, as well as de novo or previous use of enfuvirtide 
were balanced between the etravirine and the placebo groups.
Virologic response was significantly superior in the etra-
virine arm compared with placebo (59.8% versus 40.2%). Core Evidence 2009:4 153
Etravirine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Plasma viremia was reduced by a mean of -2.37 log10 from 
baseline in the etravirine arm as opposed to -1.68 log10 in 
the controls. Accordingly, CD4 count increased by a mean of 
81 cells/mm3 in the etravirine arm in contrast to 64 cells/mm3 
in the placebo arm. Among patients reusing or not using enfu-
virtide in the background regimen, 56.7% achieved 50 copies 
of HIV RNA per mL with etravirine, compared with 32.7% in 
the controls. The response rate was somewhat higher and the 
difference less pronounced when enfuvirtide was used for the 
first time in conjunction with etravirine (68.3% versus 61.3%).
In addition to these clinical trials, a recently published 
case report supports the view that etravirine has high antiviral 
activity also when combined with raltegravir, a compound 
that was not available in the trials described above.49
Several analyses of NNRTI resistance patterns in clinical 
routine samples demonstrate that currently resistance to etra-
virine, as predicted by interpretation algorithms, is rare.50–55
In the DUET trials, etravirine exhibited the expected 
toxicity pattern. Of those events occurring at a rate of 10%, 
only nausea (13.9% versus 11.1% with placebo) and rash 
(16.9% versus 9.3%) were significantly more frequent with 
etravirine. Severe reactions such as Stevens-Johnson syn-
drome, hypersensitivity reactions, and erythema multiforme 
occurred in fewer than 0.1% of patients. The rash resembled 
that observed during efavirenz treatment and led to dis-
continuation in only 2% of all patients in phase III studies. 
Other, less frequent, adverse events were widely distributed 
and probably represent the toxicity of the background com-
bination as well. Of note, neuropsychologic side effects that 
frequently limit the use of efavirenz were not reported more 
frequently with etravirine.
Regarding quality of life, functional status, adherence, 
or symptom relief, there is as yet no published information 
from the etravirine trials.
As a consequence of the unmet needs described above, 
the features of the ideal product in the setting of NNRTI 
failure can be described as follows.
1.  Lack of cross resistance within the NNRTI drug class.
2.  No pharmacokinetic interactions with other antiretroviral 
drugs (especially ritonavir-boosted protease inhibitors), 
concomitant  medication  (eg,  anticonvulsants, 
lipid-lowering drugs, and antigastritic agents), and life-
style or illicit drugs (eg, methadone, PDE-5 inhibitors).
3.  Different  profile  of  side  effects  (especially  no 
neuropsychologic impairment, few allergic reactions).
4.  Convenient pill count and dosing intervals (“one pill once 
a day”), comparable to efavirenz.
5.  Lack of teratogenicity.
To what extent does etravirine fulfil these criteria?
1.  It is highly active against resistant variants carrying key 
mutations such as K103N. However, accumulation of 
several NNRTI resistance mutations results in increasing 
degrees of cross resistance.56 The drug should therefore 
be considered earlier during NNRTI failure and not be 
withheld until patients have failed for longer. Although 
it is not licensed for this indication, the drug might be 
useful in the setting of transmitted NNRTI resistance.
2.  It is mainly metabolized via CYP3A4. This results in 
numerous interactions, especially with protease inhibitors 
and the R5 coreceptor blocker, maraviroc, that have to be 
considered when composing a regimen. The same applies 
to concomitant medication that is metabolized via the 
same pathway. Moreover, in an aging patient population, 
more interaction with concomitant medication has to 
be expected. Some interactions are unexpected57 and 
preclude the use in some combinations. The lack of 
pH dependence of absorption58 and the absence of QTc 
prolongation,59 however, are positive features.
3.  The rate of neuropsychologic side effects appears to 
be very low if at all different from placebo. Rash was 
observed with etravirine also.
4.  Despite pharmacokinetic properties that would probably 
allow for once-daily dosing, this has not been pursued in 
clinical trials, mainly due to difficulties in formulation. 
The pill count is relatively high in comparison with the 
other NNRTIs, although it is comparable with ritonavir-
boosted protease inhibitors.
5.  Etravirine does not appear to be teratogenic in animal 
models,1 but there are no reported observations during 
pregnancy.
Several aspects regarding the optimal position of etravirine 
in antiretroviral therapy remain to be investigated.
1.  Use as a stand-alone third agent. The DUET trials have 
demonstrated high activity in combination with ritonavir-
boosted darunavir, which was a novel compound when 
the studies started. Many study participants had low 
baseline resistance to darunavir, so that the results do not 
only reflect the effect of etravirine. Accordingly, in the 
TMC125-C223 trial, etravirine was used in conjunction 
with a ritonavir-boosted protease inhibitor. In the 
TMC125-C227 trial, in which it was applied as a stand-
alone third agent, it showed little activity. This, however, 
may have been a problem of patient selection. It remains 
to be shown if – in a setting of less extensive baseline 
resistance or even wild-type virus -the drug could 
be used as a substitute for efavirenz or nevirapine, Core Evidence 2009:4 154
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eg, in subjects with transmitted NNRTI resistance or in 
case of intolerance.
2.  Extent of pharmacokinetic interactions. Gender and 
ethnic differences in metabolism as well as interactions 
with concomitant medication have to be explored in 
further studies in order to provide physicians with proper 
dose recommendations.
3.  Potential for once-daily dosing. Several antiretroviral 
compounds can be given once daily. For etravirine, 
however, the high pill burden of the current formulation 
represents an obstacle to this strategy.
Economic evidence
The following calculations are subject to price changes, 
and prices may vary in different countries. They are only 
meant to assess the order of magnitude of economic 
implications. Etravirine is currently sold at a price that results 
in an approximate yearly cost of $US9500 (http://www.
healthpricer.com and http://www.pharmacychecker.com, 
accessed for update 15.7.2009). This compares favorably with 
the annual cost of other drugs licensed for use in later lines of 
therapy: $US11900 for darunavir 600 mg qd plus $US1, 350 
for ritonavir boosting; $US11590 for raltegravir; $US12070 
for maraviroc 150/300 mg twice daily; $US12370 for tiprana-
vir plus $US2700 for ritonavir boosting; and approximately 
$US29360 for enfuvirtide. It is, however, more expensive than 
the other compounds of the class: $US7700 for delavirdine; 
$US4360 for nevirapine; and $US6910 for efavirenz.
Treatment with efavirenz and nevirapine was shown to be 
cost effective or cost saving in all lines of therapy in compari-
son with protease inhibitor-based regimens.60 There are, as 
yet, no published cost-effectiveness studies using etravirine 
data. Given a lower price than protease inhibitors and enfu-
virtide, however, there is no indication that it could be less 
cost effective than enfuvirtide61 in later lines of therapy.
Resource utilization
Etravirine is currently placed in later lines of therapy for 
patients with NNRTI resistance and protease inhibitor pre-
treatment. Primary virologic failure rates are decreasing,62 
as is the risk and prevalence of triple-class resistance.63,64 
Triple-class failure occurs slowly65 and is lower among 
patients who initiated a modern HAART regimen as 
opposed to those initiated on suboptimal regimens.66 This 
currently limits the use of etravirine to a relatively small 
percentage of patients. Furthermore, the overall prevalence 
of high-level antiretroviral drug resistance is decreasing, 
probably due to improved therapeutic options with the 
novel compounds (tipranavir, darunavir, maraviroc, and 
raltegravir). Therefore, only a small fraction of all patients 
receiving antiretroviral treatment still have uncontrolled 
replication of NNRTI-resistant viruses at present and would 
be candidates for etravirine therapy. There are currently 
no data to support the use of etravirine as a replacement 
for other active compounds in a suppressive regimen, such 
as enfuvirtide, maraviroc, and raltegravir, which are more 
expensive. Replacement would be attractive for patients expe-
riencing injection-site reactions to enfuvirtide and could help 
to reduce the overall cost of therapy. However, switch trials 
are needed in order to assess if etravirine is sufficiently active 
when given without a ritonavir-boosted protease inhibitor.
Assuming that these results were favorable, etravirine 
could also represent an option for subjects with primary, 
transmitted NNRTI resistance, especially since it is not 
always detected by standard sequencing techniques. This 
would affect ∼5%–10% of newly infected individuals and 
lead to a broader use of the compound.
Patient group/population
Antiretroviral-experienced adult patients with evidence of 
viral replication and HIV-1 strains resistant to a NNRTI 
and other antiretroviral agents are likely to benefit most 
from etravirine, as long as the number of NNRTI resistance 
mutations is limited. An analysis of a large Italian resistance 
database (ARCA) suggests that exposure to nevirapine 
is associated with a higher risk of etravirine-associated 
resistance mutations than efavirenz.55 Therefore, etravirine 
appears to be used most effectively in subjects failing on 
efavirenz rather than nevirapine. Although the K103N 
mutation alone does not confer resistance to the drug, the 
presence of Y181V, G190S, V179D/F/T, or three or more 
2007 lAS-USA-defined NNRTI amino acid changes is 
associated with a markedly decreased response.
Of note, no benefit was shown in the TMC125-C227 trial, 
when etravirine was used only in combination with nucleoside/
nucleotide reverse transcriptase inhibitors in patients who failed 
an NNRTI-based regimen. Therefore, use in the absence of other 
active “flanking” agents should be avoided where possible.
In the absence of any unexpected severe toxicity, 
improved virologic suppression will likely translate into 
improved immune reconstitution and clinical stability.
Dosage, administration,  
and formulation
Etravirine (Intelence) is available as 100 mg tablets, 
and is taken as two tablets twice daily following a meal. Core Evidence 2009:4 155
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Ingestion in the fasted state results in a 50% reduction in 
systemic exposure [area under the curve (AUC)].1 The AUC 
is minimally reduced by ranitidine (14%), and increased by 
41% by omeprazole,58 which appears clinically irrelevant. 
Etravirine is a substrate of CYP 3A4, 2C9, and 2C19. 
It is also an inducer of CYP3A4, but an inhibitor of 2C9 
and 2C19. Therefore, a careful evaluation of drug inter-
actions with protease inhibitors, maraviroc [dose adjust-
ment necessary,67 and concomitant therapy is required. 
Etravirine should not be coadministered with tipranavir/
ritonavir [etravirine exposure reduced],68 fosamprenavir/
ritonavir [fosamprenavir exposure increased],69 and 
atazanavir/ritonavir [atazanavir exposure decreased],70 as well 
as with unboosted protease inhibitors and other NNRTIs. No 
dose adjustment is required for either compound in combina-
tions with lopinavir/ritonavir.71 For darunavir/ritonavir, no 
impact on darunavir levels but a decrease in etravirine AUC 
by 37% was observed in healthy volunteers.72 Given the high 
antiviral activity of this combination in the DUET studies, 
however, no dose adjustment is recommended.
For possibly interacting concomitant medication such 
as antiarrhythmics and warfarin, dose adjustment and/or 
discontinuation should be considered. Due to its long 
terminal half-life of 41 (±20) hours, treatment interruption 
or permanent discontinuation should probably be handled in 
the same way as with efavirenz, ie,continuation of the other 
drugs for some days after discontinuation of the NNRTI. 
Etravirine appears to have the potential for once-daily dosing, 
providing that the number of pills can be reduced in a future 
formulation. However, as the drug is being developed for 
later lines of therapy in which many other components are 
also dosed twice daily, this matter does not appear as a 
limitation to its use.
Etravirine has no clinically relevant effect on the 
pharmacokinetics of methadone.73
Place in therapy
Etravirine has its place in therapy in patients with virus 
resistant to NNRTI and other antiretroviral agents car-
rying limited numbers of the aforementioned NNRTI 
resistance-associated amino acid changes. This has already 
been implemented in the current Department of Health and 
Human Services (DHHS) and European AIDS Clinical 
Society (EACS) guidelines for antiretroviral therapy in 
adults.74–76 The drug is very valuable in increasing the number 
of drug options available to construct a well-tolerated and 
fully suppressive regimen and to contribute to clinical 
stability or improvement.
A limitation to its use is the fact that the favorable data 
leading to licensure were obtained only in combinations with 
ritonavir-boosted protease inhibitors. Although the label 
allows for other combinations, these data are still lacking 
and should be provided by further studies. It also has to 
be kept in mind that, due to unfavorable pharmacokinetic 
interactions, the drug can not be combined freely with 
all ritonavir-boosted protease inhibitors (see above), 
which might preclude its optimal use in some patients. 
Nevertheless, the lack of pharmacokinetic interaction with 
methadone makes it uncomplicated in patients on methadone 
substitution.
There are currently only limited pediatric data. Exposure 
of children 6–17 years of age to 4 mg/kg of bodyweight twice 
daily resulted in exposure similar to that of adults using 
200 mg twice daily,77 but studies on antiviral efficacy are 
lacking. Furthermore, there is as yet no experience during 
pregnancy. Because of lack of reproductive toxicity in animal 
models at an exposure similar to therapeutic levels in humans, 
etravirine was labelled Pregnancy Category B.1 Although its 
use during pregnancy cannot be encouraged, pregnancies will 
likely occur in women receiving etravirine. These events 
should be recorded and evaluated in the registry supported 
by the manufacturer.
It is unclear if etravirine can actually replace fully active 
compounds in a salvage treatment regimen rather than being 
added as another active component. This strategy should be 
investigated in clinical trials.
If the galenic preparation can be improved further 
and the pill burden reduced, the long half-life would 
probably allow for once-daily dosing. This would make 
the drug more attractive for first-line therapy, but it could 
also be valuable for later lines. This use, however, is not 
supported by data so far and cannot be recommended at 
the present time.
In conclusion, etravirine is a valuable novel tool in 
the armamentarium of antiretroviral drugs. It could be 
valuable for earlier lines of failure, without a ritonavir-
boosted protease inhibitor, and for primary NNRTI 
resistance, provided clinical trials show favorable results. 
Efforts should be made to further explore the potential of 
this drug.
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